Lex­i­con grabs co-pro­mo op­tion on di­a­betes drug; Shkre­li ju­ry en­ters sec­ond day of de­lib­er­a­tions

→ Lex­i­con Phar­ma­ceu­ti­cals $LXRX is tak­ing a co-pro­mo­tion op­tion on its SGLT 1 / 2 drug so­tagliflozin for type 1 di­a­betes. Lex­i­con plans to mar­ket along­side Sanofi in the US, de­cid­ing to go ahead with the op­tion af­ter look­ing over pos­i­tive late-stage da­ta for the drug, which is be­ing lined up for a mar­ket­ing ap­pli­ca­tion.

→ In­vi­tae Corp. $NV­TA is buy­ing two di­ag­nos­tics com­pa­nies. It ac­quired Com­bi­Ma­trix for $27 mil­lion and Good Start Ge­net­ics for a mix of cash and stock. And to pay for it the biotech raised $73.5 mil­lion through the sale of shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER